Free shipping on all orders over $ 500

Arzoxifene hydrochloride

Cat. No. M28925
Arzoxifene hydrochloride Structure
Synonym:

LY353381 hydrochloride; SERM III hydrochloride

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Arzoxifene (LY353381) hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.

Chemical Information
Molecular Weight 512.06
Formula C28H30ClNO4S
CAS Number 182133-27-3
Form Solid
Solubility (25°C) DMSO 25 mg/mL (ultrasonic and warming and heat to 60°C)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Steven R Goldstein, et al. Menopause. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

[2] D L Kendler, et al. Osteoporos Int. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis

[3] R W Downs Jr, et al. Osteoporos Int. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass

[4] Michael B Sporn. Clin Cancer Res. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer

[5] Cynthia L Bethea, et al. Psychoneuroendocrinology. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques

Related Estrogen Receptor Products
hFSH-β-(33-53) TFA

hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells.

Yp537

Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor.

Palazestrant

Palazestrant is a novel, orally active, estrogen receptor antagonist and selective estrogen receptor degrader. It can be used in studies related to ER+/HER2+ breast cancer.

Acolbifene hydrochloride

Acolbifene hydrochloride is an active metabolite of EM800 and an orally available, selective estrogen receptor modulator (SERM) that inhibits estradiol-induced ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM) transcriptional activity, has significant anti-estrogenic effects on the mammary gland and uterus, and has anticancer activity. possesses anticancer activity.

Acolbifene

Acolbifene is an active metabolite of EM800 and an orally active pure anti-estrogen and selective estrogen receptor (ER) antagonist that inhibits estradiol-induced ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM) transcriptional activity and has anticancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Arzoxifene hydrochloride, LY353381 hydrochloride; SERM III hydrochloride supplier, Estrogen Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.